Brief: Celltrion's Regdanvimab Shows Strong Neutralising Activity Against Delta Variant In Animal Test
July 16 (Reuters) - Celltrion HealthCare Co Ltd 091990.KQ :
* CELLTRION’S MONOCLONAL ANTIBODY TREATMENT FOR COVID-19,
REGDANVIMAB (CT-P59), DEMONSTRATES STRONG NEUTRALISING ACTIVITY
AGAINST DELTA VARIANT
* CELLTRION GROUP - REGDANVIMAB (CT-P59) ALSO RETAINED ITS
NEUTRALISATION POTENCY AGAINST THE LAMBDA VARIANT USING A
PSEUDO-VIRUS NEUTRALISATION ASSAY
* CELLTRION - ANNOUNCES RESULTS FROM GLOBAL PHASE III
CLINICAL
TRIAL OF REGDANVIMAB (CT-P59) AT ECCMID 2021
* CELLTRION - RESULTS SHOW 100% SURVIVAL RATE WITH VIRUS
ERADICATION FROM ALL ANIMALS TREATED WITH THERAPEUTIC DOSAGE OF
CT-P59
Source text for Eikon: ID:nBw6vhWWwa
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap